在这一发现的基础上,研究团队开发了一种双特异性树突状细胞-T细胞接合剂(Bispecific DC-T Cell Engager,BiCE)双抗,促进PD-1+T细胞和cDC1之间物理相互作用,该双抗的两个抗体臂分别连接两种不同细胞,一个与T细胞(CD8)结合,靶向PD-1,另一个树突状细胞(cDC1)结合,靶向CLEC9A。 在创造了这种BiCE双抗后,研究团队...
2024年1月18日,以色列Weizmann科学研究所的研究人员在Cell期刊发表了题为:Bispecific dendritic-T cell engager potentiates anti-tumor immunity的研究文章。 1.背景 使用抗PD-1(aPD-1)单克隆抗体的免疫检查点抑制治疗是一种有前景的癌症免疫治疗方法。然而,它对肿瘤免疫的影响范围较窄,因为大多数患者对该治疗没有反...
求翻译:Bispecific T cell-engager是什么意思?待解决 悬赏分:1 - 离问题结束还有 Bispecific T cell-engager问题补充:匿名 2013-05-23 12:21:38 双特异性T细胞接合 匿名 2013-05-23 12:23:18 (Bispecific T细胞允诺 匿名 2013-05-23 12:24:58 Bispecific T隐含对参与 匿名 2013-05-23 12:26:...
Bispecific T-cell engager (BiTE) immunotherapy is a promising therapy for cancer treatment. However, the high cost and short life-time in vivo of the BiTE limit its wide clinical application. Here, we built for the first time a gene delivery system based on MIL-88A metal organic framework ...
The schematic representation of structure and mechanism of action of canonical bispecific T-cell engager (BiTE). mAb: Monoclonal antibody; VH: Heavy chain variable region; VL: Light chain variable region; TAA: Tumor-associated antigen Full size image ...
AMG 420 (Amgen) is a bispecific T-cell engager that targets theB-cell maturation antigenon multiple myeloma cells and CD3 on T cells. “In this first-in-human study, AMG 420 — a short half-life bispecific T-cell engager m...
Bispecific T cell engager therapy for refractory rheumatoid arthritis 双特异性T细胞接合剂治疗难治性类风湿关节炎 相关领域 Blinatumoab公司 类风湿性关节炎 医学 B细胞 T细胞 免疫学 CD19 抗体 免疫系统 网址 https://doi.org/10.1038/s41591-024-02964-1 ...
A Bispecific γδ T-cell Engager Targeting EGFR Activates a Potent Vγ9Vδ2 T cell-Mediated Immune Response against EGFR-Expressing Tumors 2023, Cancer Immunology Research γδ T cells in immunotherapies for B-cell malignancies 2023, Frontiers in Immunology Progress in construction of mouse models ...
Optimizing anti-CD3 affinity for effective T cell targeting against tumor cells. Eur. J. Immunol. 32, 3102–3107 (2002). CAS PubMed Google Scholar List, T. & Neri, D. Biodistribution studies with tumor-targeting bispecific antibodies reveal selective accumulation at the tumor site. mAbs 4,...
Various approaches of T-cell-based cancer immunotherapy are currently under investigation, among these are BiTE (bispecific T-cell engager) antibody constructs, which have a unique design and mechanism of action. They are constructed by genetically linking onto a single polypeptide chain the minimal ...